Pharmacodynamics of antimicrobial drugs

Infectious Disease Clinics of North America

Volumn 18, Issue 3, 2004, Pages 451-465

  Levison, Matthew E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BACTERICIDE; BETA LACTAM DERIVATIVE; CARBAPENEM; CEFOPERAZONE; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; NAFCILLIN; PENICILLIN G; QUINOLONE DERIVATIVE; STREPTOGRAMIN; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CHRONOTHERAPY; ENDOCARDITIS; GRAM NEGATIVE SEPSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW; SIDE EFFECT; VESTIBULAR DISORDER;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 4043065085     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2004.04.012     Document Type: Review

References (33)

1. Ingerman M.J., Pitsakis P.G., Rosenberg A.F., et al. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental Pseudomonas endocarditis in the rat. J Infect Dis. 153:1986;707-714
2. Stevens D.L., Yan S., Bryant A.E. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis. 167:1993;1401-1405
3. Craig W.A. Basic pharmacodynamics of antimicrobials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am. 17:2003;479-502
4. Barza M., Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother. 15:(Suppl A):1985;59-75
5. Lutsar I., McCracken G.H., Friedland I.A. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 42:1998;2650-2659
6. Lamer C., deBeco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 37:1993;281-286
7. Ambrose P.G., Bhavnani S.M., Owens R.C. Clinical pharmacodynamics of quinolones. Infect Dis Clin N Am. 17:2003;529-543
8. Brook I. Inoculum effect. Rev Infect Dis. 11:1989;361-368
9. Bodey G.P., Ketchel S.J., Rodriguez V., et al. A randomized trial of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 67:1979;608-616
10. Paterson D., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 39:2001;2206-2212
11. Chambers H.F., Kennedy S. Effects of dosage peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 34:1990;510-514
12. Houlihan H.H., Mercier R.C., Ryback M.J. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother. 41:1997;2497-2501
13. Lepper M., Dowling H. Treatment of pneumococcal meningitis with penicillin compared with penicillin plus aureomycin. Arch Intern Med. 88:1951;489-494
14. Drusano G.L. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl. 74:1991;235-248
15. Lacy M.K., Nicolau D.P., Nightingale C.H., Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 27:1998;23-27
16. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 27:1998;33-39
17. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 37:1993;1073-1081
18. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am. 17:2003;503-528
19. Woodnut G. Pharmacodynamics to combat resistance. J Antimicrob Chemother. 46:2000;25-31
20. Lister P.D., Sanders C.C. Pharmacodynamics of moxifloxacin, levofloxacin, and sparfloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. J Antimicrob Chemother. 47:2001;811-818
21. Preston S.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 279:1998;125-129
22. Moore R.D., Leitman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ration of peak concentration to minimum inhibitory concentration. J Infect Dis. 155:1987;93-99
23. Rybak M.J., Abate B.J., Kang S.L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 43:1999;1549-1565
24. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 39:1995;650-655
25. Watling S.M., Dasta J.F. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 27:1993;351-356
26. Maglio D., Nicolau D.P., Nightingale C.H. Impact of pharmacodynamics on dosing of macrolides, azalides and ketolides. Infect Dis Clin N Am. 17:2003;563-577
27. Andes D., van Ogtrop M.L., Peng J., Craig W.A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 46:2002;3484-3489
28. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 42:2003;1411-1423
29. Cha R., Akins R.L., Ryback M.J. Linezolid, levofloxacin and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Pharmacotherapy. 23:2003;1531-1537
30. Jacqueline C., Batard E., Perez L., et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother. 46:2002;3706-3711
31. Conte J.E., Golden J.A., Kipps J., Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 26:2002;1475-1480
32. Ambrose P.G., Bhavnani S.M., Owens R.C. Clinical pharmacodynamics of quinolones. Infect Dis Clin N Am. 17:2003;529-543
33. Jacobs M.R. Optimization of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 7:2001;589-596